Testing spinal fluid in EGFR-mutant lung cancer with brain covering spread
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial looks at spinal fluid (also called CSF) in adults with EGFR-mutant lung cancer that has spread to the lining around the brain/spinal cord. The goal is to better understand the disease and what the spinal fluid tests may show to guide care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign consent for study procedures
- You have metastatic non-small cell lung cancer with an EGFR mutation confirmed by lab testing
- You have evidence of leptomeningeal disease (the lining around the brain/spinal cord) from brain MRI or a spinal fluid test
- Your overall condition is moderate to okay for study testing (ECOG 0 to 3)
- You are expected to live at least 8 weeks and have blood and organ function adequate for testing
- You can safely have a lumbar puncture (spinal tap) to collect CSF
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This trial tests if giving a higher dose of a third-generation EGFR-targeted pill (like osimertinib) along with chemotherapy injected into the spinal fluid can help people with advanced lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases) after standard doses stopped working. The goal is to see if this combination works better than just the higher dose of the pill alone.
This trial tests combining a targeted pill (firmonertinib) with medication injected into the fluid around the spine for people with a specific type of lung cancer that has spread to the lining of the brain. It may offer a new option if you have already tried other EGFR drugs and are still having progression.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This trial tests a combination of three drugs (pemetrexed given into the spinal fluid, high-dose furmonertinib by mouth, and bevacizumab) for people with a specific type of lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastases). The goal is to see if this treatment can help control the cancer in this hard-to-treat area.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.